Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-4,576
Closed -$367K 3691
2025
Q4
$367K Sell
4,576
-2,554
-36% -$214K ﹤0.01% 2273
2025
Q3
$696K Sell
7,130
-15,145
-68% -$1.22M ﹤0.01% 1704
2025
Q2
$1.55M Sell
22,275
-32,488
-59% -$1.85M 0.01% 1044
2025
Q1
$2.72M Buy
+54,763
New +$3.46M 0.02% 679
2024
Q4
Sell
-126,021
Closed -$13.2M 2353
2024
Q3
$13.2M Buy
+126,021
New +$14.7M 0.07% 189
2024
Q1
Sell
-28,219
Closed -$3.66M 2208
2023
Q4
$3.66M Buy
+28,219
New +$3.89M 0.03% 410
2023
Q1
Sell
-28,095
Closed -$2.23M 2414
2022
Q4
$2.23M Buy
+28,095
New +$1.98M 0.03% 538
2022
Q3
Sell
-22,216
Closed -$1.22M 2711
2022
Q2
$1.22M Buy
+22,216
New +$1.29M 0.01% 800
2021
Q3
Sell
-12,502
Closed -$505K 3217
2021
Q2
$505K Buy
+12,502
New +$518K ﹤0.01% 1762

Other funds holding ACLS

HRT Financial's ACLS Position: Q1 2026 in Review

HRT Financial sold out of Axcelis (ACLS) in Q1 2026, closing a stake of 4,576 shares — an estimated $367K sold.

HRT Financial first reported a position in ACLS in Q2 2021 and held it in 9 quarters. The position peaked at $13.2M in Q3 2024. 377 funds tracked by Wall St. Rank hold ACLS as of Q1 2026.

  • HRT Financial reported no remaining Axcelis position as of Q1 2026 after selling out during the quarter.
  • HRT Financial sold 4,576 Axcelis shares in Q1 2026, an estimated $367K.
  • HRT Financial first reported a position in Axcelis in Q2 2021 and held it in 9 quarters.
  • HRT Financial's Axcelis position peaked at $13.2M in Q3 2024.
  • 377 funds tracked by Wall St. Rank held Axcelis as of Q1 2026.

Based on HRT Financial's 13F filing for Q1 2026, filed 14 May 2026.